Skip to content

Eyedrop Instillation Technique

Eyedrop Instillation Technique: A Randomizaed Controlled Trial

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01417689
Enrollment
230
Registered
2011-08-16
Start date
2011-08-31
Completion date
2012-03-31
Last updated
2011-08-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Glaucoma, Glaucoma Suspect

Keywords

glaucoma, randomized controlled trial, eye drops, instillation, compliance

Brief summary

Eye drop instillation is a problem from glaucoma patients. Studies reveal that 30-50% of glaucoma patients have problems instilling their eyedrops. These problems include not hitting the eye, spending many drops to get a single successful instillation and bottle contamination. The present study will evaluate the effect of encouraging patients to put their eyedrops using one of 2 techniques, randomly assigned, to determine which is more successful at instilling the eye drop into the eye while spending the least amount of drug. In one of the techniques the patient instills the eye drop with their eyes open in the inferior cul de sac. In the other technique the patient instills the eye drop with the eyes closed near the inner canthal region. Patients will be randomized to encouragement to use the drops with either of the techniques. Encouragement will take place over a visit where they will be subjected to: * Baseline evaluation of eye drop instillation using their usual technique. * Short (2-5 minute) educational session session for the assigned technique. * Followup evaluation immediately after the educational session.

Interventions

OTHEREncouragement to attempt eye drop instillation with a specific technique

Encouragement to one of the 2 techniques (open eyes and closed eyes) is accomplished through a standardized educational session designed to take2-5 minutes.

Sponsors

Oftalmologia Hospital Sotero del Rio
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Glaucoma or glaucoma suspect * Use of topical glaucoma medication in both eyes for at least 1 year prior to enrollment * VA of 20/60 or better with habitual correction in at least one eye

Exclusion criteria

* Previous history of allergy to fluorescein * Received topical anesthesia for IOP measurement or other reason within the last 2 hours. * Rejects participation

Design outcomes

Primary

MeasureTime frameDescription
Complete successDay 1. Immediately after intervention.Total success is defined as: Patient manages to instill one eyedrop into de eye spending only one eye drop. Difference in the proportion of patients achieving successful eye drop instillation in each of the 2 groups. For the main analysis the results of the first eye (Right or left randomly determined will be used) A mixed model with both eyes in the analysis will also be presented for sensitivity analysis.

Secondary

MeasureTime frameDescription
Qualified successDay 1. Same day as intervention.Qualified success is defined as: Patient manages to instill one eye drop into the eye regardless of the amount of drops spent. Difference in the proportion of patients achieving successful eye drop instillation in each of the 2 groups. For the main analysis the results of the first eye (Right or left randomly determined will be used) A mixed model with both eyes in the analysis will also be presented for sensitivity analysis.
Number of dropsDay 1.Number of eye drops spent on attempted instillation in the first eye (randomly assigned). The average number of drops spent on each of the groups will be compared. Mixed models with data from both eyes will also be presented for sensitivity analysis.

Countries

Chile

Contacts

Primary ContactMilitza Sanchez, COT
militza_a@hotmail.com+56982382507

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026